Switch to:
More From Other Websites
Shire's (SHPG) ADHD Candidate's NDA Accepted by FDA Jan 20 2017
Is Shire plc a Great Stock for Value Investors? Jan 19 2017
7:01 am Shire announces that the FDA has acknowledged receipt of the Class 2 resubmission of an NDA... Jan 19 2017
U.S. FDA Acknowledges Receipt of Shire's New Drug Application for SHP465 for ADHD Jan 19 2017
SHIRE PLC Files SEC form 8-K, Financial Statements and Exhibits Jan 17 2017
FTSE 100 continues record run, rising for 14th day in a row Jan 13 2017
KemPharm CEO On Recent Results, Catalysts And Prospects: 'ADHD Is By Far The Larger Market... Jan 12 2017
Lawsuit accuses Shire of monopolizing market for ADHD drug Jan 12 2017
PRESS DIGEST- Financial Times - Jan 12 Jan 11 2017
[$$] Shire to Pay $350 Million to Settle Dermagraft Kickback Allegations Jan 11 2017
Pharmaceutical company agrees to ‘landmark’ settlement in Tampa federal court Jan 11 2017
Trump slams drug industry at press conference, sending biotech stocks tumbling Jan 11 2017
FTSE 100 logs 10th day of all-time highs Jan 11 2017
Shire CEO: Our innovation score is very high Jan 10 2017
Martin Whitman Invests in Homebuilder in 4th Quarter Jan 09 2017
Merrimack Pharma to Sell Cancer Drugs for $1B Jan 09 2017
SHIRE PLC Files SEC form 8-K, Financial Statements and Exhibits Jan 06 2017
For Shire PLC (ADR) (SHPG) Securing Hemophilia Market With Long Acting Version Is Crucial Jan 06 2017
Director Declaration Jan 06 2017
Here's what to expect from Mass. biotechs at this weekend's J.P. Morgan conference Jan 05 2017


Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK